Eledon Pharmaceuticals, Inc. (ELDN)

Over the past six months, Eledon Pharmaceuticals' stock has experienced significant volatility. In November 2025, the stock plunged dramatically following mixed results from its Phase 2 BESTOW clinical trial. In December 2025, news reports indicated biotech momentum carrying after-hours trading gains. In March 2026, Eledon reported its fourth quarter and full year 2025 operating and financial results, highlighting progress in advancing tegoprubart and the FDA granted Orphan Drug designation for liver transplantation. In early 2026, the stock price has risen significantly, driven by positive news regarding tegoprubart's early success in human clinical trials. In April 2026, BlackRock reported a stake in Eledon and Eledon proposed a share authorization increase. In May 2026, the company is estimated to announce its Q1 2026 earnings.

There is no explicit information indicating demand seasonality for Eledon Pharmaceuticals, Inc.'s products or services. As a clinical-stage biotechnology company, its primary focus is on research and development of therapies, rather than the commercial sale of established products, making traditional demand seasonality not applicable.

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing immune-modulating therapies for life-threatening conditions, operating within the Healthcare sector, specifically in the Biotechnology industry, and utilizing its immunology expertise to target the CD40 Ligand (CD40L) pathway. The company's primary product in development is tegoprubart, an IgG1 anti-CD40L antibody, being investigated for prevention of allograft rejection in kidney and liver transplantation, xenotransplantation, islet cell transplantation for Type 1 Diabetes, and treatment of amyotrophic lateral sclerosis (ALS).

Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California, United States. The company's clinical development efforts have a global reach, as evidenced by its Phase 2 BESTOW trial for kidney transplant recipients, which enrolled patients across 44 global sites.

Eledon Pharmaceuticals' brand reputation has been influenced by both setbacks and positive developments related to tegoprubart. In November 2025, the company's reputation faced a challenge when its Phase 2 BESTOW trial failed to meet its primary efficacy endpoint. In early 2026, Eledon has seen a positive shift in its reputation, particularly within the Type 1 Diabetes community, due to early success of tegoprubart in human clinical trials.

Eledon Pharmaceuticals stock ownership is a mix of institutional, retail, and individual investors. Institutional investors hold approximately 16.14% of the company's stock, with major shareholders including BVF Inc/il, Vanguard Group Inc, and BlackRock, Inc. Insiders own approximately 0.03% of the company's stock. Public companies and individual investors hold a significant portion, around 83.83% of the stock.